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Isomeric N-Benzyl-3-[(chlorophenyl)amino]propanamides were prepared through an uncatalysed amine 
exchange reaction with benzylamine. The structures of these compounds were established through 
various spectroscopic techniques. The compounds were screened in mice against maximal electroshock 
(MES) and subcutaneous pentylene tetrazole (scPTZ) seizure test models as well as the righting reflex 
test for neurological deficit in mice. The isomers of N-Benzyl-3-[(chlorophenyl)amino] propanamide  were 
found to be active both in the MES and scPTZ tests. The ortho and para isomers were found to be more 
potent than the standard drug (phenytoin) in the MES test, while all the 3 isomeric benzylated products 
were found to be far more potent than valproate in both the MES and the scPTZ tests with favourable 
therapeutic indices signifying their great potential for use against generalized seizures. Acute toxicity 
studies revealed that N-Benzyl-3-[(chlorophenyl)amino]propanamides  are relatively safe.  
Keywords: Epilepsy, anticonvulsants, N-Benzyl-3-[(chlorophenyl)amino]propanamide  
 
INTRODUCTION 
Epilepsy is a common neurological condition, affecting 
0.5 to 1 % (45-100 million people) of the population 
worldwide  (Bell and Sander, 2002). Conventional 
antiepileptic drugs (AEDs) phenobarbital, primidone, 
phenytoin, carbamazepine, ethosuximide and 
benzodiazepine, are widely used but exhibit an 
unfavorable side effect profile and failure to 
adequately control seizures (Zahn et al., 1998; Battino 
et al., 2000, Brunton et al., 2009). In the recent years 
several new drugs (oxcarbazepine, lamotrigine, 
topiramate, gabapentin, zonisamide, tiagabine, 
fosphenytoin, vigabatrin and felbamate) have been 
added to the list of therapeutic agents against 
epilepsy. However, there is a significant group of 
patients (up to 30 %) who are resistant to the available 
antiepileptic drugs (Avanzini and Franceschetti, 2003 
and Brunton et al., 2009). The long-established AEDs 
control seizures in 50% of patients developing partial 
seizures, and in 60-70 % of those developing 
generalized seizures (Lopes Lima, 2000; Prucca, 
2002; Berk et al., 2001; Duncan, 2002 and Eadie, 
2001). Hence, there is an urgent need to develop new 
AEDs (Szelenyi et al., 2003 and Voskoyl and Clincker, 
2009).The search for antiepileptic compounds with a 
more selective activity and lower toxicity continues to 
be an area of investigation in medicinal chemistry.  
Recently, a series of carboxamides 
possessing the anilide pharmacophore were 
synthesized and screened for anticonvulsant activity in 
our laboratory (Idris et al., 2008a, 2008b, and 2008c). 
Subsequently, we studied the effect of N-benzylation 
at the amido nitrogen of a section of these 
carboxamides (the anisidinopropanamides and 
toluidinopropanamides) and found  that, consistent 
with earlier observations (Clark et al., 1984; Choi et 
al., 1996; Ho et al., 2001), compounds with improved 
anticonvulsant profile resulted (Idris et al., 2009 ; Idris 
et al.,2010). In this study we report the effect of N-
benzylation at the amido nitrogen on the 
anticonvulsant activity of isomeric 3-
[(chloropheny)amino]propanamides. 
 
MATERIALS AND METHODS 
Equipments 
All melting points were determined using an 
Electrothermal melting point apparatus (Model 2038A 
– England). Elemental carbon, hydrogen and nitrogen 
were determined with a Parkin Elmer model 240 
elemental analyzer (University of leads, England). 
Chlorine  was determined by the Schrodinger 
combustion (University of Leeds, England). IR spectra 
were recorded on a Parkin Elmer paragon 1000 as 
KBr disc (University of Readings, U.K.). Mass spectra 
were measured on an AP2000 (IS, 70ev) instrument 
(University of Leads, England). Proton and carbon-13 
NMR (1H NMR and 13CNMR) spectra were recorded 
on a Brǜker CWM 250 (250 MHz), or a Joel AL -300 
spectrometer (JAPAN) with TMS as an internal 
standard. The equipment for the MES screening is an 
Ugo Basile electroconvulsive unit (ECT 800) fitted with 
ear clip electrodes.  
Chemicals 
Starting materials were Analar grade and used without 
further purification. 2-, 3- and 4-
[(chloropheny)amino]propanamides used were 
prepared in the post graduate research laboratory, 
Department of Pharmaceutical and Medicinal 
Chemistry, Ahmadu Bello University, Zaria, Nigeria. 
Benzylamine, propylene glycol, iodine crystals and 
potassium permanganate were all obtained from BDH 
chemicals (Pools, England). The solvents (benzene, 
methanol, chloroform and ethyl acetate were also 
obtained from BDH chemicals (Pools, England). 
Phenytoin and pentylenetetrazole (PTZ) were 
obtained from Sigma-Aldrich (St Louis MO) and 
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Animals   
Swiss albino (male) mice in the weight range 18-30g 
were used. The animals were inbred in the animal 
house of the Department of Pharmacology and 
Therapeutics, Faculty of Pharmaceutical Sciences, 
Ahmadu Bello University, Zaria. The animals were 
kept under standard laboratory conditions 
(temperature 25±30C; humidity 45 – 60% and 12 
hours light/dark cycle) and were allowed free access 
to both food (Vital feeds mixed with fish and groundnut 
cake) and water except when they were removed from 
their cages for the experiments. 
Synthesis 
The 3-[(chlorophenyl)amino]propanamides (3-CAP) 
were previously prepared through Michael reaction 
between the chloroanilines and acrylamide in the 
presence of catalytic amounts of p-toluenesulphonic 
acid (P-TOSA), according to scheme 1 (Idris, 2008) 
NH2
Cl





                                                                 Chloroaniline                        Acrylamide                               3-[(chlorophenyl)amino]propanamide 
Scheme 1 Synthesis of the 3-[(chlorophenyl)amino]propanamides 
Conversion of 3-[(chlorophenyl)amino]propanamides (3-CAP) to the N-benzyl-3-
[(chlorophenyl)amino]propanamides (NB-3-CAP) was achieved by an uncatalysed amine exchange reaction with 






 Anisidinopropanamide                                  Benzylamine                               N-benzyl-3-[(chlorophenyl)amino]propanamide 
 
Scheme 2. Conversion of 3-CAP to NB-3-CAP 
 
General Procedure for the synthesis 
Progress of all the reactions were monitored using thin 
layer chromatography (TLC) with ethyl acetate as 
development solvent. Purity of starting materials and 
of end products were also assessed using TLC. 
Chromatograms were visualized under U.V 
fluorescence quenching at 254m or by staining with 
potassium permanganate solution or iodine vapour. All 
absorptions are reported in terms of frequency of 
absorption (cm-1). Data for \1HNMR and 13CNMR are 
reported as follows; chemical shift (δ ppm), integration 
and coupling constant in Hz, Multiplicity: s = singlet, d 
= doublet, t = triplet, q = quartet, m = multiplet. Data 
for 13CNMR are reported in terms of chemical shift. 
 
Preparation of the N-benzyl-3-
[(chlorophenyl)amino]propanamides  
 A mixture of about 0.22mole each of the 3-
[(clorophenyl)amino]propanamide and benzylamine 
was refluxed on oil bath (170-1800C) for about 48 
hours. The set up was allowed to cool to room 
temperature and the solid formed was digested in 
chloroform and collected by filtration. The products 
were recrystallized in benzene/toluene until a single 
spot was obtained on TLC. The yields and physical 
properties of the compounds were recorded (Idris, 
2008). 
 
Screening for anticonvulsant activity  
Anticonvulsant screening was established by both 
electrical and chemical procedures as described by 
Swinyard et al., (1989). Neurotoxicity was assessed 
according to the procedure described by Swinyard et 
al., (1952). Each animal was examined for its 
neurological status before the administration of the 
test drug. Screenings were conducted at 0.5 and 4hrs 
after injection of the test compound. All quantitative 
determinations were carried out at the estimated time 
of peak anticonvulsant activity of the candidate 
compounds.  
 
a) Primary (Qualitative) Evaluation of the 3-
[(chlorophenyl)amino]propanamides  
i) The Maximal Electroshock Seizure (MES) Test:  
48 male albino mice (18-30g) were randomly divided 
into six groups of 8 mice per group. Three groups 
received intraperitoneal (ip) injection of 30, 100 and 
300mg/kg respectively of the test compound 
(dissolved in propylene glycol) while the control group 
received 25mg/Kg propylene glycol solution (i.p). The 
other two groups received 20mg/Kg (i.p) of phenytoin 
and valproic acid respectively. An electrical stimulus 
(50mA at 60Hz for 0.2sec) was delivered through ear 
clip electrodes using an Ugo Basile electroconvulsive 
generator. Abolition of the hind limb tonic extensor 
component indicates the compounds ability to inhibit 
MES-induced seizure spread 
 
ii)    The subcutaneous Pentylenetetrazol (scPTZ) 
Seizure Test   
40 male albino mice (18-30g) were randomly divided 
into five groups of 8 mice per group. Three groups 
received intraperitoneal (ip) injection of 30, 100 and 
300mg/kg respectively of the test compound 
(dissolved in propylene glycol) while the other 2 
groups received 25mg/kg of the vehicle and 20mg/kg 
valproic acid IP respectively. 85mg/kg 
pentyleneterazole (metrazole) was injected 
subcutaneously. The mice were observed for 30 
minutes for the occurrence of seizures. Absence of 
clonic spasms in the observed time period indicates a 
compounds ability to abolish the effect of 
pentylenetetrazole on seizure threshold (Swinyard et 
al.,1989) 
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iii) Determination of Minimal Neurotoxicity 
32 male albino mice were randomly divided into 4 
groups of eight mice per group. The first, second and 
third groups were given 30, 100 and 300mg/kg of the 
compound respectively, while the last group was given 
25mg/kg propylene glycol (ip). The mice were placed 
on their back. Neurological deficit was indicated by 
inability of the animal to quickly resume their normal 
posture. The number of mice that showed signs of 
neurotoxicity at various dose levels was recorded 
(Swinyard et al., 1952)       
 
b)  Secondary (Quantitative) Evaluation of the 3-
Benzyl-3[(chlorophenyl)amino]pro-panamides            
i)   Determination of time of peak anticonvulsant effect 
Maximum electroshock (MES) method was employed 
for the determination. 100mg/kg of the compound was 
injected intraperitoneally to four groups of mice, each 
group consisting of six mice. The first group was 
subjected to MES at 15 minutes, while the second, 
third and fourth, were given at 30, 45 and 60, minutes 
respectively. In each case the number of mice 
protected was recorded. From the data the time of 
peak anticonvulsant activity was determined (Stables 
and Kupferberg, 1977) 
 
ii) Determination of Minimal Neurotoxicity (TD50):  
Groups of eight mice were given graded doses of the 
candidate compound such that two points were 
established between limits of 100 percent toxicity and 
zero percent toxicity. The animals were subjected to 
righting test as described above. The number of mice 
that showed sign of neurotoxicity at various dose 
levels was recorded and the TD50 was determined 
using graphical method of Miller and Tainter (1994).       
 
iii)  Determination of the median effective dose (ED50) 
 Several groups of at least eight mice per group 
received various doses of the candidate compound 
until at least two points were established between the 
limits of 100 percent protection and zero percent 
protection using the MES, and ScPTZ tests as 
described above. The ED50 was calculated using the 
graphical method of Miller and Tainter (1994).   
 
Acute Toxicity Studies of 3-Benzyl-3-
[(chlorophenyl)amino]propanamides in Mice (LD50) 
LD50 determination was conducted using the method 
of Lorke (1983). In the initial investigation mice were 
divided into three groups of three mice each, treated 
with the drugs at 10, 100 and 1000mg/kg body weight 
intraperitoneally (ip), and observed for 24 hours for 
signs of toxicity and death. The results of these tests 
were used as the bases for selecting the subsequent 
dosages. The LD50 was calculated as the square root 
of the product of the lowest dosage that killed all the 
animals and the highest dosage survived by the entire 
animal in the group.   
  
RESULTS 
Student’s T-test was used to determine level of 
significance of all results obtained. Results were 
regarded as significant at P<0.05.
  
 
Table 1: Physicochemical Properties of N-benzyl- 3-[(chlorophenyl)amino]propanamides 
Comp. Physical appearance M. pt. ( 0C) % Yield RT (minutes) 
2-Cl Dirty white crystals        159 – 161            73.70        35.125 
3-Cl          White granules        142 – 143            81.20         32.194 
4-Cl           Pale yellow crystals        153 – 154     76.42        29.332 
 
Table 2: Results of Microanalysis of Isomeric N-benzyl-3-[(chlorophenyl)amino]pro-panamides 
Comp. Elem. 
Comp 




C Found (Cal) H Found (Cal) N Found ( Cal) 
2-Cl C, H,N   71.91 (71.83)   7.14 (7.04) 9.97 (9.97) 284 C17H20N2O2 
3-Cl C,H,N 71.87 (71.83) 7.12 (7.04) 9.91 (9.86) 284 C17H20N2O2 
4-Cl C,H,N 71.93 (71.83) 7.15 (7.04) 9.96 (9.86) 284 C17H20N202 
 























































































































Table 4: 1HNMR Specra Data for Isomeric N-benzyl- 3-[(chlorophenyl)amino]propane-mides  
 
2-Cl δ(ppm) 7.59-7.57 (t, 1H, 3J13,14 = 5.0,Ar-NH-, H-11), 7.28-7.24 (m, 2H, 3J15,14 = 7.83, 3J15,16 = 7.05, 3J11,18 = 
7.83, 3J =7.05, 2Ar-H-15 and H-17), 7.17-7.12 (t, 1H, 3J16,15 = 7.05, 3J16,17 = 7.05, Ar-H, H-16), 7.06-7.02 (d; 1H, 
3J514 = 8.11, Ar-H, H-5), 7.04 -7.02 (t, 1H, 3J3,2 = 7.24, 3J3,2 = 8.11, Ar-H, H-3), 6.96-6.93 (d, 1H, 3J2,3 = 8.11, Ar-H, 
H-2), 6.87-6.85 (dd, 2H, 3J14,15 = 7.83, 3J18,17 = 7.83, 2Ar-H, H-14, H-18), 6.77 (s, 1H, Ar-NH-, H-7), 6.75-6.72 (t, 
1H, 3J4,3 = 8.11, 3J4,5 = 7.84, Ar-H, H-4), 4.54-4.52 (d, 2H 3J12,11 = 5.0, -NH-CH2-Ar, H-12), 3.18-3.16 (d, 2H, 3J8,9 
= 7.34, -NH-CH2-CH2, H-8), 2.55-2.5 (t, 2H,3J9,8 = 7.34, -NH-CH2-CH2, H-9) 
 
3-Cl δ(ppm) 9.26 (S, 1h, Ar-NH-, H-7), 7.60-757 (t, 2H, 3J11,12 = 5.0, -CO-NH-, H-11), 28-7.23 (m, 3J15,14 = 
7.83,3J15,16 = 7.05, 3J17,18 7.83, 3J17,16= 7.05 2Ar-H, H-15 and H-17), 7.17-7.13 (t, 1H, 3J16,15 = 7.05, 3J16,17 = 7.05, 
Ar-H, H-16), 6.99-6.98 (t, 1H, 3J3,2 =8.2, 3J3,4 = 8.04, Ar-H, H-3), 6.94-6.94 (s, 1H, Ar-H, C-6).6.89- (d, 1H, 3J2,3 
8.2, Ar-H, H-2), 6.88-6.85 (dd, 2H, 3J14,15 ==7.83, 3J18,17 = 7.83, H-14, H-18), 4.54-4.52 (t, 2H, 3J12,11 = 5.0, -CO-
NH2-CH2-, H-12), 3.23-3.19 (t, 2H, 3J8,9 = 7.34, Ar-NH-CH2-CH2-, H-8), 2.55-2.51 (t, 2H, 3J9,8 = 7.34,-NH-CH2-
CH2-, H-9). 
 
4-Cl δ(ppm) 8.67 (s, 1H, Ar-NH,H-7), 7.6-7.59 (t, 1H, 3J11,12 = 5.0, -CO-NH, H-11), 7.58-7.55 (dd, 2H, 3J2,3 = 8.71, 
3J6,5 = 8.71, 2Ar-H, H-2 and H-6), 7.30-7.28 (dd, 2H, 3J3,2 = 8.71, 3J5,6 = 8.71, 2Ar-H, H-3 and H-5), 7.27-7.23 
(m,2H, 3J15,14 = 7.83, 3J15,16 =7.05, 3J17,16 = 7.05, 3J17,18 =7.83, 2Ar-H H-15, H-17), 7.17-7.12 (t, 1H, 3J16,15 = 7.05, 
3J17,16 = 7.05, Ar-H, H-16), 687-6.85 (dd, 2H, 3J14,15 = 7.83, 3J18,17 = 7.83, 2Ar-H, H-14 and H-18), 4.54-4.521 (d, 
2H, 3J12,11 = 5.0, -NH-CH2-Ar, H-12), 324-3.19 (t, 2H, 3J8,9 = 7.34, -NH-CH2-CH2- H-8), 2.55-2.51 (t, 2H 3J9,8 = 
7.34, -NH-CH2-CH2, H-9). 
 
Table 5.  13C-NMR Spectra for the N-benzyl-3-[(chlorophenyl)amino]propanamide. 
2-Cl 171.70 (1C,-CO- C-10), 167.00 (1C, ArC, C-1), 137.60 (1C, Arc, C-13), 128.82 (1C, ArC, C-5), 128.71 (2C, 
ArC, C-14 &C-18), 128.60 (2C, ArC, C-15 and C-17), 127.40 (1C, ArC, C-16), 125.80 (1C, ArC, C-4), 119.08 (1C, 
ArC, C-6), 111.03 (1C, ArC, C-2), 42.53 (1C, -NH-CH2-Ar, C-12), 39.90 (1C,-NH-CH2-CH2, C-8), 32.33 (1C,-NH-
CH2- CH2-, C-9). 
 
3-Cl (ppm) 171.70 (1C,-CO-C-10), 146.11 (1C, ArC, C-1), 137.60 (1C, ArC, C-13), 133.58 (1C, ArC, C-5), 128.97 
(1C, ArC, C-3), 128.71 (2C, ArC, C-14 & E18), 128.60 (2C, ArC, C-15 and C-17), 127.40 (1C, ArC, C-16), 122.22 
(1C, ArC, C-4), 117.60 (1C, ArC, C-6), 115.11 (1C, ArC, C-2), 42.53 (1C, -NH-CH2-Ar, C-12), 39.90 (1C, -NH-
CH2-CH2, C-18), 32.33 (1C, -NH-CH2-CH2-, C.9) 
 
4-Cl δ(ppm) 171.70 (1C,-CO-, C-10) 148.72 (1C, Ar-C, C-1), 137.60 (1C, Ar-C, C-13), 130.02 (2C, Ar-C, C-
2andC-6), 128.60 (2C, ArC, C-15 and C-17), 127.04 (1C, ArC,C-16), 121.70 (1C, ArC, C-4), 113.53 (2C, ArC, C-
3, & C-5), 42.53 (1C,-NH-CH2-Ar, C-12), 39.90 (1C, -NH-CH2-CH2, C-8), 32.33 (1C, -NH-CH2-CH2- C-9). 
 
Table 6: Results for Phase I Anticonvulsant Screening of Isomeric N-Benzyl-3-
[(chlorophenyl)amino]propnamides in MES and scPTZ Tests and the Righting Reflex Test in Mice. 
______________________________________________________________________________________ 
COMP         Protection against                 Protection against            Protection against   
     MES Induced Seizures  scPTZ Induced Seizures   RightingReflex Text    
                       0.5hr              4hrs              0.5hr       4hrs             0.5hr       4hrs 
______________________________________________________________________________________ 
2-Cl           +++   +++         +++          +++       ++         + 
3-Cl            ++    ++         ++            ++              ++       ++                       
 4-Cl            +++    ++         +++          +++      +++                   
CONT*    -                   -            -              -                     -       -                
 
Statistical analysis was conducted by the student T-test p< 0.05 compare to vehicle treated control groups; Key. 
+++: activity at 30mg/kg; ++; activity at 100 mg/kg; +; activitiy at 300 mg/kg; - no activity even at 300 mg/kg or not 
determined; *Control group was given propylene glycol (vehicle) 25mg/kg. 
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ED50 #,+ scPTZ 
 
TD50#,+ 




 9.20 (8.35 – 11.01) 
 
 15.70 (8.98 - 27.30) 
 








 23.40 (15.50 - 35.40) 
 
25.30 (16.00 – 40.00) 
 








 5.15 (26.37 – 34.31) 
 
  11.18 (6.39 – 17.15) 
 







        












 271.54(246.93-337.85)  
 
148.49(122.95-176.95)  














Key: #:   All doses are measured in mg/kg, b:   95% confidence limits are given parentheses, (-): Means no 
activity at 100mg/kg, *: Control group was given propylene glycol (vehicle) 25mg/kg 
 
Table 8: Results of acute toxicity test (LD50) for the N-Benzyl- 3-[(chlorophenyl) amino]propanamides 
                              Compound                       LD50 ( mg/kg) 
                              2-Cl                       811.50 
                              3-Cl                       7I4.80 
                              4-Cl                       987.47 
 
DISCUSSION 
Melting points are uncorrected. The ortho isomer of 
the N-benzyl-3-[(clorophenyl)amino]propanamides has 
a higher melting point than the other two isomers 
(table 1), very much unlike what obtains in the methyl 
and methoxy analogues of the anilinopropanamides 
where the para isomers have the higher melting points 
(Idris et al, 2009; Idris et al., 2010). Moreover, the 
product yields (81-73%) are better than were for the 
other two isomers. The results for micro analytical 
studies are given in Table 2 and are within ± 0.4 
percent of theoretical values. Thus, we had no 
problem establishing the empirical formula and, by 
extension, the molecular formula (having obtained the 
molecular weight from the mass spectra). The IR 
spectra show prominent peaks at 3390-3375 cm-1 (-N-
H stretching vibrations), 3169-3060cm-1 (aromatic =C-
H stretching frequencies), 1632-1606 cm-1 (aromatic 
carbon-carbon stretching vibrations), 1647-1627cm-1 
(carbonyl frequency vibrations usually referred to as 
amide band I), 1527-1514cm-1 (N-H deformation 
usually referred to as amide band II), 1299-1280cm-1 
(-C-N stretching frequencies of secondary amines), 
1099-10560cm-1 (in plane bending vibrations of 
methylene groups) and 833-678cm-1 (out of plane 
bending vibrations) (table 3) (Kalsi, 2007). The 
fragmentation pattern in the mass spectra is typical of 
secondary amines, the most prominent peaks 
occurring at m/z (%intensity) 288 (40, M+) and 140 
(100).The proton positions are as indicated in Table 4. 
Coupling protons were detected using correlated 
spectroscopy (COSY) and the J values were 
estimated using a computer ACD software. The result 
of DEPT analysis revealed X-CH, Y-CH2, Z-CH3 and 
quaternary carbons (table 5). 2-D NMR spectra were 
used to establish connectivity between fragments.          
 Anticonvulsant activity was defined by 
obtaining percentage response of at least 37.5 (or a 
quantal response of 3/8).  In the preliminary 
investigation, all the three isomers of the N-benzyl-3-
[(chlorophenyl)amino]propanamides showed good 
activity in both the MES and scPTZ tests at a dose of 
30mg/kg, 0.5hr and 4.0hrs after intraperitoneal 
injection of the drugs (Table 6). The results for the 
quantitative analysis are given in Table 7. On a 
general note, and, as observed in the methyl- and 
methoxy- analogues   (Idris et al., 2009; Idris et al., 
2010), N-benzylation at the amido nitrogen brought 
about increase in anticonvulsant potency and a 
broadening of the spectrum of activity of the 3-
anilinopropanamides. The margin of safety of these 
compounds also improved following N-benzylation. 
Even in the case of the ortho-substituted isomer where 
there was a small decease in potency(MES ED50  
9.20mg/kg : 5.07mg/kg; Sc-PTZ ED50  15.70mg/kg : 
12.70mg/kg  ), the therapeutic index increased [PI 
(TD50/ED50) 3.60: 2.00] showing the extent to which N-
benzylation favourably affects the quality of these 
compounds as candidate anticonvulsant agents. 
Furthermore, prior to the benzylation the   para chloro 
isomer was the least potent of the three 3-
chloroanilinopropanamides against electrically induced 
seizure. N-benzylation reverses this order. N-Benzyl-
3-[(4-chlorophenyl)anino]-propanamide (the para 
chloro isomer) is now the most potent isomer (MES 
ED50  = 5.15mg/kg) with an incredibly high therapeutic 
index [PI (TD50/ED50) =13.6]. For the meta isomer, N-
Benzylation caused increase in potency in both MES 
and sc-PTZ tests (MES ED50 23.40mg/kg : 
30.70mg/kg; sc-PTZ ED50  25.30mg/kg : over 
100mg/kg  ).  It could therefore be said that the N-
benzyl-3-[(clorophenyl)amino]propanamides are 
similar to valproate in their ability to inhibit MES and 
scPTZ-induced seizures in mice although they are by 
far more potent. The compounds therefore have the 
potential for being useful in the treatment of 
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CONCLUSION 
N-benzylation of the 3-[(clorophenyl) 
amino]propanamides  at the amido nitrogen modifies 
their anticonvulsant property. While these compounds 
protect the animals against MES-induced seizures 
their N-benzyl counterparts inhibit both MES- and 
scPTZ-induced seizures. Consequently, the N-benzyl-
3-[(clorophenyl)amino]propanamides  have the 
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